Explore first-line EGFR-mutated NSCLC options, when to intensify beyond osimertinib, and how brain/liver mets, ctDNA, TP53, and comorbidities guide choices.
Amy Cummings, MD, PhD,
Advertisement
Articles by Amy Cummings, MD, PhD,
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Advisory Committee to Weigh RP1 Plus Nivolumab in Anti–PD-1–Pretreated Advanced Melanoma
3
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5